Skip to main content

Advertisement

Figure 5 | Breast Cancer Research

Figure 5

From: Benefits and harms of mammography screening

Figure 5

Twenty year risk for diagnosis of, and death from, breast and prostate cancer with and without screening in the United Kingdom [ 49 ] . Displayed are 20-year absolute risks for incidence (including overdiagnosis) and mortality with and without screening. Overdiagnosis is set to 45% for prostate cancer and 22% for breast cancer, respectively (age 50 to 69 years). Mortality reduction is set to be 20% for both cancers (age 55 and 74 years). For prostate cancer, the estimates are based on the observed incidence and mortality in 1998 (before any widespread use of prostate-specific antigen (PSA)) and for breast cancer in 2007 (latest data available).

Back to article page